Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile

For the past 40 years, metal-based drugs have been widely used for the treatment of cancer. Cisplatin and follow-up drugs carboplatin (ParaplatinTM) and oxaliplatin (EloxatinTM) have been the gold standard for metallodrugs in clinical settings as antineoplastic agents. While effective, these drugs (...

Whakaahuatanga katoa

I tiakina i:
Ngā taipitopito rārangi puna kōrero
Kaituhi matua: Contel, Maria
Hōputu: Online
Reo:Ingarihi
I whakaputaina: MDPI - Multidisciplinary Digital Publishing Institute 2021
Ngā marau:
Urunga tuihono:42560
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
_version_ 1869527044072669184
author Contel, Maria
author_browse Contel, Maria
author_facet Contel, Maria
author_sort Contel, Maria
collection Directory of Open Access Books
description For the past 40 years, metal-based drugs have been widely used for the treatment of cancer. Cisplatin and follow-up drugs carboplatin (ParaplatinTM) and oxaliplatin (EloxatinTM) have been the gold standard for metallodrugs in clinical settings as antineoplastic agents. While effective, these drugs (either alone or in combination therapy) have faced a number of clinical challenges resulting from their limited spectrum of activity, high toxicity leading to significant side effects, resistance, poor water solubility, low bioavailability and short circulating time. In the past 10 years, various unconventional non-platinum metal-based agents have emerged as a potential alternative for cancer treatment. These compounds are highly effective and selective in cancers resistant to cisplatin and other chemotherapeutic agents. Research in this area has recently exploded with a relevant number of patents and clinical trials, in addition to reports in scientific journals. Furthermore, in parallel to the synthesis of coordination and organometallic compounds comprising many different metals and unconventional platinum-based derivatives, researchers are focused on optimizing mechanistic and pharmacological features of promising drug candidates. This Special Issue aims to highlight the latest advances in anticancer metallodrugs with a focus on unconventional anticancer agents, as well as novel activation, targeting and delivery strategies aimed at improving their pharmacological profile.
format Online
id doab-20.500.12854ir-61518
institution Directory of Open Access Books
language eng
publishDate 2021
publishDateRange 2021
publishDateSort 2021
publisher MDPI - Multidisciplinary Digital Publishing Institute
publisherStr MDPI - Multidisciplinary Digital Publishing Institute
record_format ojs
spelling doab-20.500.12854ir-615182024-04-05T12:33:19Z Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile Contel, Maria QH301-705.5 QD415-436 Q1-390 ?–? stacking encapsulation n/a oxindolimine–metal complexes cyclodextrin platinum iodido complexes distribution coefficient antiproliferative activity anticancer agents nanotubes ruthenium platinum Log kw nanoparticles drug discovery metal complex metallodrugs isatin-derived ligands anticancer drug upconverting nanoparticles pyridine benzimidazole dendrimers liposomes thiophene angiogenesis micelles HSA oxidation platinum(IV) imaging chromatographic lipophilicity parameter amidophosphine copper and iron chelators in cancer Log P biomacromolecules bones DNA cleavage stopped-flow spectroscopy silver phosphonates transmetalation metallomics MRI fluorescence quenching partition coefficient gold fingers anticancer HSA binding gold ?0 targeting metastasis DNA interaction antimigration cytotoxicity HPLC ruthenium complexes zinc finger proteins Gold(III) complexes aquaporins antiproliferative protein-DNA recognition photoactivation lipophilicity cancer 1-methylcytosine PET thema EDItEUR::P Mathematics and Science::PS Biology, life sciences For the past 40 years, metal-based drugs have been widely used for the treatment of cancer. Cisplatin and follow-up drugs carboplatin (ParaplatinTM) and oxaliplatin (EloxatinTM) have been the gold standard for metallodrugs in clinical settings as antineoplastic agents. While effective, these drugs (either alone or in combination therapy) have faced a number of clinical challenges resulting from their limited spectrum of activity, high toxicity leading to significant side effects, resistance, poor water solubility, low bioavailability and short circulating time. In the past 10 years, various unconventional non-platinum metal-based agents have emerged as a potential alternative for cancer treatment. These compounds are highly effective and selective in cancers resistant to cisplatin and other chemotherapeutic agents. Research in this area has recently exploded with a relevant number of patents and clinical trials, in addition to reports in scientific journals. Furthermore, in parallel to the synthesis of coordination and organometallic compounds comprising many different metals and unconventional platinum-based derivatives, researchers are focused on optimizing mechanistic and pharmacological features of promising drug candidates. This Special Issue aims to highlight the latest advances in anticancer metallodrugs with a focus on unconventional anticancer agents, as well as novel activation, targeting and delivery strategies aimed at improving their pharmacological profile. 2021-02-12T06:53:10Z 2021-02-12T06:53:10Z 2019-12-09 11:49:15 2019 book 42560 9783039213160 9783039213153 https://directory.doabooks.org/handle/20.500.12854/61518 eng application/octet-stream Attribution-NonCommercial-NoDerivatives 4.0 International https://mdpi.com/books/pdfview/book/1637 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-03921-316-0 10.3390/books978-3-03921-316-0 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783039213160 9783039213153 204 open access
spellingShingle QH301-705.5
QD415-436
Q1-390
?–? stacking
encapsulation
n/a
oxindolimine–metal complexes
cyclodextrin
platinum iodido complexes
distribution coefficient
antiproliferative activity
anticancer agents
nanotubes
ruthenium
platinum
Log kw
nanoparticles
drug discovery
metal complex
metallodrugs
isatin-derived ligands
anticancer drug
upconverting nanoparticles
pyridine benzimidazole
dendrimers
liposomes
thiophene
angiogenesis
micelles
HSA oxidation
platinum(IV)
imaging
chromatographic lipophilicity parameter
amidophosphine
copper and iron chelators in cancer
Log P
biomacromolecules
bones
DNA cleavage
stopped-flow spectroscopy
silver
phosphonates
transmetalation
metallomics
MRI
fluorescence quenching
partition coefficient
gold fingers
anticancer
HSA binding
gold
?0
targeting
metastasis
DNA interaction
antimigration
cytotoxicity
HPLC
ruthenium complexes
zinc finger proteins
Gold(III) complexes
aquaporins
antiproliferative
protein-DNA recognition
photoactivation
lipophilicity
cancer
1-methylcytosine
PET
thema EDItEUR::P Mathematics and Science::PS Biology, life sciences
Contel, Maria
Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile
title Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile
title_full Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile
title_fullStr Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile
title_full_unstemmed Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile
title_short Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile
title_sort unconventional anticancer metallodrugs and strategies to improve their pharmacological profile
topic QH301-705.5
QD415-436
Q1-390
?–? stacking
encapsulation
n/a
oxindolimine–metal complexes
cyclodextrin
platinum iodido complexes
distribution coefficient
antiproliferative activity
anticancer agents
nanotubes
ruthenium
platinum
Log kw
nanoparticles
drug discovery
metal complex
metallodrugs
isatin-derived ligands
anticancer drug
upconverting nanoparticles
pyridine benzimidazole
dendrimers
liposomes
thiophene
angiogenesis
micelles
HSA oxidation
platinum(IV)
imaging
chromatographic lipophilicity parameter
amidophosphine
copper and iron chelators in cancer
Log P
biomacromolecules
bones
DNA cleavage
stopped-flow spectroscopy
silver
phosphonates
transmetalation
metallomics
MRI
fluorescence quenching
partition coefficient
gold fingers
anticancer
HSA binding
gold
?0
targeting
metastasis
DNA interaction
antimigration
cytotoxicity
HPLC
ruthenium complexes
zinc finger proteins
Gold(III) complexes
aquaporins
antiproliferative
protein-DNA recognition
photoactivation
lipophilicity
cancer
1-methylcytosine
PET
thema EDItEUR::P Mathematics and Science::PS Biology, life sciences
topic_facet QH301-705.5
QD415-436
Q1-390
?–? stacking
encapsulation
n/a
oxindolimine–metal complexes
cyclodextrin
platinum iodido complexes
distribution coefficient
antiproliferative activity
anticancer agents
nanotubes
ruthenium
platinum
Log kw
nanoparticles
drug discovery
metal complex
metallodrugs
isatin-derived ligands
anticancer drug
upconverting nanoparticles
pyridine benzimidazole
dendrimers
liposomes
thiophene
angiogenesis
micelles
HSA oxidation
platinum(IV)
imaging
chromatographic lipophilicity parameter
amidophosphine
copper and iron chelators in cancer
Log P
biomacromolecules
bones
DNA cleavage
stopped-flow spectroscopy
silver
phosphonates
transmetalation
metallomics
MRI
fluorescence quenching
partition coefficient
gold fingers
anticancer
HSA binding
gold
?0
targeting
metastasis
DNA interaction
antimigration
cytotoxicity
HPLC
ruthenium complexes
zinc finger proteins
Gold(III) complexes
aquaporins
antiproliferative
protein-DNA recognition
photoactivation
lipophilicity
cancer
1-methylcytosine
PET
thema EDItEUR::P Mathematics and Science::PS Biology, life sciences
url 42560
work_keys_str_mv AT contelmaria unconventionalanticancermetallodrugsandstrategiestoimprovetheirpharmacologicalprofile